Results 81 to 90 of about 16,179 (202)

Biomarkers of Leucine‐Rich Repeat Kinase 2 (LRRK2) and Lysosomal Dysfunction in Progressive Supranuclear Palsy

open access: yesMovement Disorders, EarlyView.
Abstract Background Common and rare genetic variants in leucine‐rich repeat kinase 2 (LRRK2) have been linked with sporadic and familial Parkinson's disease (PD). Recently, we discovered that common genetic variation near the LRRK2 locus determined survival in progressive supranuclear palsy (PSP).
Louise‐Kristine Nielsen   +27 more
wiley   +1 more source

Co‐ and Multi‐Pathologies in Parkinson's Disease: An International Parkinson and Movement Disorder Society Scientific Issues Committee Review

open access: yesMovement Disorders, EarlyView.
Abstract Parkinson's disease (PD) has been historically defined as a disease of striatal dopamine deficiency secondary to degeneration of dopaminergic neurons in the substantia nigra pars compacta, related to the presence of Lewy bodies and Lewy neurites.
Michele Matarazzo   +10 more
wiley   +1 more source

Interventions in progressive supranuclear palsy

open access: yesParkinsonism & Related Disorders, 2016
Progressive supranuclear palsy (PSP) an atypical parkinsonian with a common phenotype comprising early falls, the characteristic slowing of vertical saccades and a frontal syndrome with marked apathy (Richardson's syndrome). Currently, no effective symptomatic or neuroprotective treatment is available for PSP. Current medical have a limited role in PSP.
Koros, C., Stamelou, M.
openaire   +3 more sources

Asymmetric Upper Limb Dysfunction Demonstrated at the Bedside: A Phenomenology Video

open access: yes
Movement Disorders Clinical Practice, EarlyView.
Gero Lueg   +4 more
wiley   +1 more source

A Brainstem Radiomics Framework to Distinguish Progressive Supranuclear Palsy from Parkinson's Disease

open access: yesMovement Disorders, EarlyView.
Abstract Background Differentiating progressive supranuclear palsy (PSP) from Parkinson's disease (PD) can be clinically challenging. In the neuroimaging field, radiomics has emerged as a promising approach to capture subtle microstructural and textural image alterations, improving differential diagnoses.
Chiara Camastra   +8 more
wiley   +1 more source

Seeing Invisible Oligomers: Rethinking α‐Synuclein Pathology Through Proximity Ligation Assay

open access: yesMovement Disorders, EarlyView.
Abstract Parkinson's disease (PD) and multiple system atrophy are defined by α‐synuclein (αSYN)‐positive inclusions – Lewy bodies (LBs) and glial cytoplasmic inclusions – yet mounting evidence indicates that these inclusions represent only a fraction of disease‐relevant pathology.
Hiroaki Sekiya   +3 more
wiley   +1 more source

Qihuang Needle Therapy for Motor Symptoms in Parkinson's Disease: A Randomized Controlled Trial

open access: yesMovement Disorders, EarlyView.
Abstract Background Motor symptoms in Parkinson's disease (PD) often respond incompletely to medication, highlighting the need for effective adjunctive therapies. Acupuncture may offer benefits, but high‐quality evidence for specialized techniques such as Qihuang needle therapy is lacking.
Wanqing Peng   +11 more
wiley   +1 more source

Imaging tau pathology in Parkinsonisms

open access: yesnpj Parkinson's Disease, 2017
The recent development of positron emission tomography radiotracers targeting pathological tau in vivo has led to numerous human trials. While investigations have primarily focused on the most common tauopathy, Alzheimer’s disease, it is imperative that ...
Sarah Coakeley, Antonio P. Strafella
doaj   +1 more source

Gray Matter Microstructure Measured Using Diffusion Imaging as a Biomarker of Severity in Lewy Body Diseases

open access: yesMovement Disorders, EarlyView.
Abstract Background Despite widespread cortical involvement in Lewy body diseases, conventional gray matter magnetic resonance imaging (MRI) shows limited sensitivity. Diffusion‐weighted MRI‐derived microstructural measures have shown utility in Alzheimer's disease, but their application across the Lewy body disease spectrum remains limited ...
Angeliki Zarkali   +9 more
wiley   +1 more source

Data‐driven thresholds for standardized classification of severe Alzheimer's disease neuropathology using digital neuropathology

open access: yesBrain Pathology, EarlyView.
We generated digital pathologic algorithms (AI‐based modules that can be freely shared) to: optimize the sampling (ROI) for diagnosis of ADNC‐related tau pathology; compare/transition between Aperio and HALO platforms; and rationalize severe Braak NFT staging, so that all Braak‐VI cases had dementia, and all Braak‐V cases had MCI or dementia.
Ryan K. Shahidehpour   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy